The administration of resveratrol can reverse multidrug resistance and in combination with cisplatin has an additive and/or synergistic effect in increasing the chemosensitivity of cancer cells, reducing cytotoxic effects on healthy cells and modulating the immune response in the tumour microenvironment by regulating cytokines/chemokines secretion, immune-checkpoints/MHCI (major histocompatibility complex 1), the nuclear factor-κB (NF-κB) signalling pathway, the AKT-mammalian target of rapamycin (mTOR) signalling, and the activation of receptors on natural killer (NK) cells [11,12]. The gene discussed is MTOR; the disease is cancer.